EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME)

EYLEA^® (aflibercept, Regeneron Pharmaceuticals) 의 적응증 추가 :

 - diabetic macular edema (DME) 에 대한 FDA 승인

 - visual acuity와 retinal vessel damage, or retinopathy 의 효과 개선

 -  2 milligrams (mg) every two months (8 weeks) after five initial monthly injections.

 

 

 

 

 

 

출처:

http://www.pipelinereview.com/index.php/2015032757269/Antibodies/EYLEA-aflibercept-Injection-Receives-FDA-Approval-for-the-Treatment-of-Diabetic-Retinopathy-in-Patients-with-Diabetic-Macular-Edema-DME.html